(Reuters) - Inovio Pharmaceuticals Inc has received U.S. health regulator's clearance to begin a mid-stage study of its COVID-19 vaccine candidate, the vaccine maker said on Monday.
The trial for the vaccine, INO-4800, will be funded by the U.S. Department of Defense, the company said.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!